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Abstract
Background: The effectiveness of injection therapy for low-back pain is still debatable. We compared the efficacy of local
injections of the homeopathic preparation Disci/Rhus toxicodendron compositum (verum) with placebo injections and with
no treatment in patients with chronic low back pain.
Methodology/Principal Findings: In a randomized controlled partly double blind multicenter trial patients with chronic low
back pain from 9 German outpatient clinics were enrolled and randomly allocated in a 1:1:1 ratio to receive subcutaneous
injections (verum or placebo) into painful sites on the lower back over 12 treatment sessions within eight weeks, or no
treatment (rescue pain medication with paracetamol or NSAIDs). All trial personnel and participants were masked to
treatment allocation. The primary outcome measure was the average pain intensity over the last seven days on a visual
analogue scale (0–100 mm, 0=no pain, 100=worst imaginable pain) after eight weeks. Follow-up was 26 weeks. Primary
analysis was by intention to treat. Between August 2007 and June 2008, 150 patients were randomly allocated to three
groups (51 verum, 48 placebo and 51 no treatment). The mean baseline-adjusted low back pain intensity at week eight was:
verum group 37.0 mm (97.5% CI 25.3;48.8), no treatment group 53.0 (41.8;64.2), and placebo group 41.8 (30.1;53.6). The
verum was significantly superior to no treatment (P=0.001), but not to placebo (P=0.350). No significant side effects were
reported.
Conclusions/Significance: The homeopathic preparation was not superior to placebo. Compared to no treatment injections
resulted in significant and clinical relevant chronic back pain relief.
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Introduction
In Western countries, chronic low back pain is a major health
concern affecting quality of life and productivity. Low back pain
has a high economic impact. More than 70% of the population in
industrialised countries are affected by low back pain [1]. In the
United Kingdom, low back pain accounts for 13% of absences due
to illness. The annual incidence in adults is up to 45%, with those
aged 35–55 years affected most often. Although 90% of episodes of
acute low back pain settle within six weeks, up to 7% of patients
develop chronic pain. For chronic low back pain, a wide range [2]
of treatment options are available although their efficacy is not
always clear. A multimodal approach is recommended including
providing information and counseling, exercise, pain therapy,
behavioral therapy, and physiotherapy [2,3,4]. However, long
term effects are difficult to achieve [4]. Treatment with
complementary and alternative medicine (CAM) therapies are
widely used [5,6,7,8,9,10].
Anthroposophic medicine is one of those CAM therapies. It was
founded in the 1920s by Rudolf Steiner and Ita Wegman and aims
to stimulate salutogenesis in patients by utilizing their self-healing
capacities [11,12]. It is practiced in around 67 countries around
the world. Anthroposophic therapy for low back pain is provided
by physicians (counseling, anthroposophic medication) and non-
medical therapists (eurhythmy therapy, rhythmical massage
therapy, embrocation, and art therapy). Anthroposophic drugs
are of mineral, botanical or zoological origin, and are mostly used
in homeopathic dilutions [11,12].
The anthroposophic drug Disci/Rhus toxicodendron composi-
tum (WALA Heilmittel GmbH) is used to treat acute low back
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indicated that it might be effective for chronic low back pain.
However, the effectiveness of injection therapy for low-back pain is
still debatable [2,13] and systematic data on the effectiveness or
efficacy of Disci/Rhus toxicodendron compositum for chronic low
back pain does not exist so far. The aim of the trial presented here
was to determine the efficacy of Disci/Rhus toxicodendron
compositum injections compared to placebo injections and no
treatment in patients with chronic low back pain.
Methods
Design
A randomized controlled partly double-blind multicenter trial
with a treatment duration of eight weeks and a follow-up after 26
weeks was performed to compare the injection of 10 ml Disci/
Rhus toxicodendron compositum (verum) to 10 ml isotonic saline
solution (placebo) and to a no treatment control. In the verum and
in the placebo group both physicians and patients were blinded to
group assignment. In addition, both participating statisticians were
blinded for data analysis.
This study followed the standards of the Declaration of Helsinki,
and the ICH-GCP guideline and was approved by the local ethics
committees (Leading Ethics Committee in Berlin at the Landesamt
fu ¨r Gesundheit und Soziales, application No. 8031/07) and the
Bundesinstitut fu ¨r Arzneimittel und Medizinprodukte (application
No. 61-3910-4032679). All patients gave written informed con-
sent. The protocol for this trial and supporting CONSORT
checklist are available as supporting information; see Checklist S1
and Protocol S1.
Participants
Patients were recruited between August 2007 and June 2008 by
nine study centers with various specializations (family medicine,
internal medicine, orthopedics, rehabilitation, university outpa-
tient clinics) in Germany. Participants in all three groups received
the therapy free of charge (the no treatment group received the
therapy after the study), but no allowance was paid. Participants
were informed of the blinded study design and the randomized
setting and the possibility of being assigned to the no treatment
group. The central randomization sequence was generated with
SAS 9.1 (SAS Institute, Cary, NC, USA) in a 1:1:1 ratio in blocks
of ten stratified for centers. Randomization envelopes were
prepared by two individuals who supervised each other and were
not further involved in the study. They prepared opaque envelopes
that were sequentially numbered and sealed, each containing a
randomization number for each patient. Envelopes were opened
by the study physician in consecutive order after gaining informed
consent and baseline data. The number in the randomization
envelope was identical with the patient code and the number on
the medication box of the respective patient. Patients were eligible
for the trial if they fulfilled the following inclusion criteria: age
from 30 to 75 years, male or female, low back pain for at least 12
months (chronic low back pain), already received standard
therapy, average back pain intensity of at least 40 mm on VAS
(0–100 mm) in the last seven days at baseline, no other treatment
except oral NSAIDs and muscle relaxants within four weeks prior
to study entry, and informed consent. Women of childbearing
potential were only included if they used effective contraceptive
methods (Pearl Index ,1).
Exclusion criteria included: previous or current treatment with
Disci preparations, treatment other than NSAIDs or peripherally
acting analgesics, routine use of analgesics for other diseases,
protrusion or prolapsed intervertebral discs (one or more) with
neurological symptoms, previous spinal surgery, suspected infec-
tious spondylopathy, low back pain because of malignant or
infectious disease, organic causes of back pain such as ankylosing
spondylitis, Reiter syndrome and Behc ¸et’ syndrome, congenital
deformities of the spine (without minor lordosis, kyphosis,
scoliosis), suspected osteoporosis with compression fracture,
suspected spinal stenosis, spondylolysis or spondylolisthesis,
physiotherapy in the last four weeks prior or planned during the
trial, the initiation of a new treatment for low back pain,
complementary treatment in the last four weeks prior to or
planned during the trial, inability to participate in the trial
effectively, alcohol or substance abuse, participation in another
clinical trial, severe chronic or acute disease which does not allow
study participation, bleeding disorders or oral anticoagulation
treatment, pregnancy and breast feeding, current application for a
benefit, involvement in planning or coordination of the study, and
hypersensitivity against drug components (Table 1).
Intervention
Patients in the two treatment groups (verum and placebo)
received 12 treatment sessions within eight weeks: twice per week
for the first four weeks (with at least one day without therapy
between sessions) and one treatment per week for the second four
weeks (with at least three days without therapy between sessions).
During each treatment session, 10 ml of solution was injected in 5
to 10 small dosages subcutaneously with a 0.4 mm needle into
painful sites on the lower back. Disci/Rhus toxicodendron
compositum is a composite medication based on the theory of
anthroposophic medicine and is authorized in Germany. It
consists of 11 different diluted agents (Table 1) and is traditionally
used to treat disturbances of the spine, particularly acute pain
associated with degenerative changes.
The placebo group received an injection with isotonic saline
solution which contained sodium chloride, sodium hydrogen
carbonate, and water and was not distinguishable from the verum
solution. Patients in the no treatment group received no additional
intervention during the study period. In all three groups, rescue
pain medication with peripherally acting analgesics (also paracet-
amol) or NSAIDs, but not pain medication acting on the central
nervous system, was permitted and their intake was documented in
diaries.
Table 1. Postulated active ingredients of Disci/Rhus
toxicodendron compositum.
Aconitum napellus e tubere ferm 33c Dil. D4 0.1 g
Argentum metallicum Dil. D18 aquos. 0.1 g
Arnica montana e planta tota ferm 33c Dil. D18 0.1 g
Disci intervertebrales bovis (cervicales, thoracici et lumbales) Gl Dil. D6 0.1 g
Formica rufa ex animale toto Gl Dil. D5 0.1 g
Gelsemium sempervirens e rhizoma ferm 35b Dil. D2 0.1 g
Granit Dil. D8 0.1 g
Leontopodium alpinum e planta tota ferm 36 Dil. D2 0.1 g
Mandragora officinarum e radice ferm 34d Dil. D4 0.1 g
Phyllostachys e nodo ferm 35c Dil. D4 0.1 g
Toxicodendron quercifolium e foliis ferm 33d Dil. D4 0.1 g
Other ingredients sodium chloride, sodium hydrogen carbonate, and water for
injection.
doi:10.1371/journal.pone.0026166.t001
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Verum n=51 No treatment n=51 Placebo n=48
mean±sd/n (%) median mean±sd/n (%) median mean±sd/n (%) median P value
$
Gender 0.030
Female 40 ( 78.4% ) 29 ( 56.9% ) 27 ( 56.3% )
Male 11 ( 21.6% ) 22 ( 43.1% ) 21 ( 43.8% )
Age (years) 58.7 6 10.9 61.0 56.7 6 10.7 58.0 54.8 6 11.3 57.0 0.223
Height (m) 167.9 6 7.2 168.0 172.0 6 8.9 170.0 172.1 6 8.3 170.0 0.014
Body weight (kg) 75.0 6 13.9 74.0 77.1 6 12.9 76.0 78.2 6 15.6 76.0 0.524
BMI (kg/m
2) 26.6 6 4.4 26.7 26.1 6 4.0 25.7 26.4 6 5.0 24.8 0.867
Average pain intensity (VAS) 58.9 6 14.3 54.0 59.0 6 14.1 55.0 62.5 6 13.9 61.5 0.360
Medication intake 22 ( 43.1% ) 20 ( 39.2% ) 15 ( 31.3% ) 0.465
Pain perception scale SES#
Affective pain 47.5 6 7.4 46.0 47.8 6 9.0 47.0 50.5 6 9.5 49.0 0.188
Sensory pain 47.5 6 8.4 46.0 49.4 6 9.0 49.0 49.6 6 9.7 48.0 0.447
Pain disability index (PDI)# 27.1 6 10.7 26.0 27.7 6 11.8 26.5 29.0 6 13.8 28.0 0.741
Back function (HFAQ)* 61.9 6 18.0 66.7 65.5 6 17.4 66.7 61.3 6 21.8 62.5 0.491
SF-36 quality of life*
Physical Component Score 36.2 6 6.3 36.5 35.1 6 7.7 35.2 31.6 6 8.9 30.5 0.010
Mental Component Score 48.8 6 12.3 54.1 49.2 6 11.0 53.3 50.5 6 11.5 53.6 0.756
Physical functioning 60.5 6 15.4 60.0 59.0 6 22.5 57.5 50.8 6 23.0 50.0 0.046
Role physical 47.6 6 38.5 50.0 35.0 6 35.4 25.0 33.9 6 35.9 25.0 0.119
Bodily pain 37.0 6 14.4 41.0 37.0 6 13.9 41.0 31.7 6 14.8 31.0 0.111
General health perception 53.7 6 17.2 53.5 56.6 6 18.0 55.0 50.8 6 19.6 47.0 0.304
Vitality 48.6 6 18.6 45.0 45.6 6 19.2 45.0 45.3 6 19.6 45.0 0.630
Social functioning 74.5 6 24.2 75.0 74.8 6 21.9 75.0 71.1 6 24.4 75.0 0.692
Role emotional 68.0 6 41.6 100.0 63.3 6 44.7 100.0 71.5 6 41.8 100.0 0.634
Mental health 68.0 6 21.1 76.0 70.0 6 17.5 76.0 67.4 6 20.0 72.0 0.789
Effectiveness of the therapy
with the verum (physician)
0.482
m
Very effective 4 ( 7.8% ) 6 ( 11.8% ) 3 ( 6.3% )
Effective 41 ( 80.4% ) 41 ( 80.4% ) 39 ( 81.3% )
Small effect 6 ( 11.8% ) 4 ( 7.8% ) 6 ( 12.5% )
No effect 0 ( 0.0% ) 0 ( 0.0% ) 0 ( 0.0% )
Effectiveness of the therapy
with the verum (patient)
0.706
m
Very effective 7 ( 14.0% ) 10 ( 20.4% ) 8 ( 17.8% )
Effective 38 ( 76.0% ) 35 ( 71.4% ) 32 ( 71.1% )
Small effect 4 ( 8.0% ) 4 ( 8.2% ) 5 ( 11.1% )
No effect 1 ( 2.0% ) 0 ( 0.0% ) 0 ( 0.0% )
Expectation of the therapy
with the verum (physician)
0.389
m
Recovery 3 ( 5.9% ) 3 ( 5.9% ) 2 ( 4.2% )
Distinct improvement 21 ( 41.2% ) 23 ( 45.1% ) 16 ( 33.3% )
Light improvement 27 ( 52.9% ) 24 ( 47.1% ) 29 ( 60.4% )
No improvement 0 ( 0.0% ) 1 ( 2.0% ) 1 ( 2.1% )
Expectation of the therapy
with the verum (patient)
0.358
m
Recovery 7 ( 13.7% ) 5 ( 9.8% ) 2 ( 4.2% )
Distinct improvement 38 ( 74.5% ) 44 ( 86.3% ) 51 ( 85.4% )
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The primary outcome measure was the average low back pain
intensity over the last seven days on a visual analogue scale [14]
(VAS, 0–100 mm, 0=no pain, 100=worst imaginable pain) after
eight weeks.
Secondary outcome measures included the VAS at 26 weeks,
and the following outcomes at eight and 26 weeks: back function
(Hannover Functional Ability Questionnaire, HFAQ; in German,
Funktionsfragebogen Hannover Ru ¨cken), [15] quality of life (SF-
36), [16] pain disability scale (PDI), [17] and pain perception scale
(SES) [18,19]. A patient diary (baseline to week 8) was used to
calculate the number of days with medication between weeks five
and eight. In addition, we evaluated the safety of the interventions
and blinding (patient guess at 8 weeks).
Verum n=51 No treatment n=51 Placebo n=48
mean±sd/n (%) median mean±sd/n (%) median mean±sd/n (%) median P value
$
Light improvement 5 ( 9.8% ) 2 ( 3.9% ) 5 ( 10.4% )
No improvement 1 ( 2.0% ) 0 ( 0.0% ) 0 ( 0.0% )
$one-way ANOVA,
#lower values are better,
*higher values are better.
mKruskal-Wallis test.
doi:10.1371/journal.pone.0026166.t002
Table 2. Cont.
Figure 1. Trial flow chart. *primary outcome parameter available and used for primary analysis.
doi:10.1371/journal.pone.0026166.g001
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ment due to the treatment before randomization, patients and
doctors had to document on categorical scales their expectation of
the therapy: ‘‘recovery’’, ‘‘distinct improvement’’, ‘‘light improve-
ment’’ and ‘‘no improvement’’; as well as their assessment of the
presumed therapy’s effectiveness: ‘‘very effective’’, ‘‘effective’’,
‘‘small effect’’ and ‘‘no effect’’.
Statistical analysis
The primary analysis population was the intention to treat (ITT)
population. Each randomized participant was included into the
analysis regardless of the adherence to the assigned treatment or
the provision of a full set of data. To detect a difference of
12.5 mm on the VAS between the verum group and the placebo
group, with a pooled standard deviation of 18 mm (medium effect
size according to Cohen d=0.69) for the primary outcome
measure with a power of 80% and an alpha-level of 2.5%
(Bonferroni correction method to adjust for the testing of two
primary analyses), a total of 123 participants were needed (41 per
group). Taking about 20% potential drop outs into account, 150
participants were planned to be included into the study. For the
primary analysis, a multilevel model with the two levels patient
and study site was fitted to the data. The model was a linear mixed
model with a random-effects parameter for study site, and
additionally included the baseline VAS value as fixed covariate.
Two primary hypotheses were tested comparing i) the verum
group with the no treatment group and ii) the verum group with
the placebo group. Both comparisons were made with the
respective two-sided Wald test at an alpha level of 2.5%
(Bonferroni correction) to set an overall significance level at 5%.
From this model we estimated adjusted treatment effects and their
confidence intervals (CI) at the 97.5%-level. Sensitivity analyses
were performed by imputing missing values of the primary
outcome using a maximum likelihood based imputation (regres-
sion method including baseline visual analogue scale, age and
gender) and a ‘‘worst case scenario’’ method (where missing values
in the verum group were imputed by the worst possible value (100)
while missing values in the placebo and no treatment groups were
imputed by the best possible value (0)). An additional per-protocol
(PP) analysis was performed which included all randomized
patients with complete primary outcome data (eight weeks), while
excluding patients who had received less than 10 treatments
during the first eight weeks or started a new therapy during the
first eight weeks or received some kind of physiotherapy or CAM
treatment during the first eight weeks. Patients were also excluded
from the PP analysis if they required pain medication other than
NSAIDs and peripherally acting analgesics or suffered from
pseudospondylolisthesis. Further secondary analyses included an
unadjusted analysis, the inclusion of other covariates into the
primary model, and the analysis of all secondary outcomes with
similar models (confidence intervals at the 95%-level for secondary
outcomes).
Results
Participants
From 369 possible participants screened, 150 were enrolled and
randomized into the three groups (verum group n=51, placebo
group n=48, no treatment n=51). The mean age was 57611
(mean6sd) years, 64% were female and the mean duration of
symptoms was 15612 years. At baseline, the average pain
intensity on the VAS was 60614 mm (Table 2). 47 patients in
the verum group and 42 patients in the placebo group received all
12 treatments (Figure 1). Eight patients were lost to follow-up at
week eight, but were included in the ITT analysis. Follow-up data
after 26 weeks was available for 136 patients (verum group n=49,
placebo group n=40, no treatment group n=47). The reasons for
missing follow-up data are shown in Figure 1. For most baseline
parameters, groups were comparable, with the exception of gender
(P=0.030), height (P=0.014), and two scales of the SF-36, the
physical component score (P=0.010) and physical functioning
subscale (P=0.046). Expected treatment outcome was also
comparable between the three groups.
Outcome measures
Figure 2 shows the result for the primary outcome measure, the
adjusted mean VAS for average low back pain intensity in the last
seven days at week eight. Average pain was 37.0 [97.5% CI
25.3;48.8] in the verum group, 53.0 [41.8;64.2] in the no
treatment group, and 41.8 [30.1;53.6] in the placebo group.
The VAS was statistically significant lower in the verum group
than in the no treatment group (P=0.001, also Table 3), but no
significant differences could be shown between the verum and the
placebo group (P=0.350). Unadjusted analysis, per-protocol
analysis, and analyses with the imputation of missing values
yielded similar results (Table 4). Moreover, the inclusion of other
Figure 2. Mean (with 95% confidence interval) pain intensity over the last 7 days (VAS) at week 8 (primary outcome) and at week
26. Differences were statistically significant for the comparison of verum and no treatment group at 8 weeks (P,0.001), but not for the comparison
with the placebo group (P=0.350) and at 26 weeks for both group comparisons (P=0.085 and P=0.837, respectively).
doi:10.1371/journal.pone.0026166.g002
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1.
Verum n=50 No treatment n=49 Placebo n=43
Verum
vs no
treatment
Verum vs
placebo
mean 95%CI mean 95%CI mean 95%CI P value P value
Average pain intensity (VAS)
8 weeks (97.5% CI) 37.0 25.3 ; 48.8 53.0 41.8 ; 64.2 41.8 30.1 ; 53.6 0.001 0.350
26 weeks 36.6 25.4 ; 47.8 45.0 34.1 ; 55.9 35.5 24.2 ; 46.9 0.085 0.837
Days with rescue medication
Week 1–4 3.9 1.1 ; 6.8 8.8 6.0 ; 11.6 2.8 20.1 ; 5.7 ,0.001 0.396
Week 5–8 3.7 1.2 ; 6.3 8.2 5.7 ; 10.7 3.3 0.8 ; 5.9 0.001 0.785
Week 1–8 7.7 2.5 ; 12.9 17.1 12.0 ; 22.2 6.0 0.7 ; 11.4 ,0.001 0.532
Pain perception scale (SES)#
Affective pain
8 weeks 44.0 41.7 ; 46.3 44.9 42.5 ; 47.3 43.5 41.0 ; 46.1 0.590 0.795
26 weeks 42.9 40.0 ; 45.7 42.1 39.3 ; 45.0 41.4 38.3 ; 44.4 0.686 0.420
Sensory pain
8 weeks 45.3 43.3 ; 47.3 45.0 43.0 ; 47.0 46.1 44.0 ; 48.2 0.811 0.594
26 weeks 45.5 42.8 ; 48.1 44.8 42.2 ; 47.4 43.7 41.0 ; 46.3 0.680 0.277
Pain disability index (PDI)#
8 weeks 22.7 19.3 ; 26.2 25.9 22.5 ; 29.3 21.4 17.7 ; 25.1 0.200 0.598
26 weeks 18.1 14.0 ; 22.3 22.7 18.7 ; 26.7 21.4 17.2 ; 25.6 0.046 0.173
Back function (HFAQ)*
8 weeks 68.3 64.0 ; 72.6 64.8 60.5 ; 69.1 68.4 63.8 ; 73.0 0.261 0.969
26 weeks 69.0 62.8 ; 75.2 64.8 58.8 ; 70.9 67.4 61.0 ; 73.8 0.226 0.660
SF-36 quality of life*
Physical component score
8 weeks 37.1 34.9 ; 39.2 35.4 33.3 ; 37.5 39.8 37.5 ; 42.1 0.278 0.089
26 weeks 38.2 35.0 ; 41.5 36.5 33.3 ; 39.7 40.9 37.5 ; 44.2 0.326 0.163
Mental component score
8 weeks 48.5 46.0 ; 50.9 50.9 48.4 ; 53.3 47.5 44.9 ; 50.1 0.174 0.609
26 weeks 51.2 48.9 ; 53.5 51.5 49.1 ; 53.9 48.9 46.4 ; 51.4 0.861 0.185
Physical functioning
8 weeks 59.6 55.2 ; 64.1 59.8 55.3 ; 64.3 64.0 59.2 ; 68.9 0.955 0.196
26 weeks 63.4 56.7 ; 70.0 60.1 53.6 ; 66.6 66.3 59.5 ; 73.2 0.370 0.439
Role physical
8 weeks 47.8 38.3 ; 57.3 47.1 37.7 ; 56.6 57.0 46.8 ; 67.2 0.919 0.198
26 weeks 54.7 42.0 ; 67.3 49.7 37.3 ; 62.1 60.5 47.4 ; 73.7 0.508 0.458
Bodily pain
8 weeks 48.0 42.6 ; 53.5 40.0 34.5 ; 45.5 46.8 40.9 ; 52.7 0.041 0.767
26 weeks 53.3 45.2 ; 61.4 46.1 38.1 ; 54.0 50.2 41.9 ; 58.5 0.085 0.483
General health perception
8 weeks 53.7 49.7 ; 57.7 52.9 48.9 ; 56.9 54.2 49.9 ; 58.5 0.773 0.878
26 weeks 54.8 50.2 ; 59.4 51.9 47.2 ; 56.5 57.1 52.1 ; 62.1 0.321 0.465
Vitality
8 weeks 45.5 41.0 ; 50.0 44.5 40.0 ; 49.0 51.1 46.3 ; 56.0 0.759 0.096
26 weeks 50.1 45.0 ; 55.3 49.2 44.2 ; 54.3 51.7 46.3 ; 57.0 0.764 0.614
Social functioning
8 weeks 73.9 68.5 ; 79.3 76.7 71.3 ; 82.2 75.4 69.6 ; 81.3 0.472 0.712
26 weeks 81.5 76.5 ; 86.5 78.2 73.0 ; 83.3 78.7 73.2 ; 84.3 0.363 0.470
Role emotional
8 weeks 75.5 65.9 ; 85.1 74.4 64.5 ; 84.3 62.5 52.1 ; 72.9 0.874 0.072
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different at baseline, did not change the results. According to
Cohen’s d the effect size for the comparison between verum and
no treatment group was moderate (0.68).[20]
After 26 weeks the average pain severity did not differ
significantly between the three groups and was lower than after
8 weeks (Table 3). A trend towards a difference between the verum
36.6 [95% CI 25.4;47.8] and the no treatment group 45.0
[34.1;55.9] after 26 weeks was revealed (P=0.085).
For most of the secondary outcomes after 8 weeks and 26 weeks,
no significant group differences were observed with the exception
of some differences between the verum and the no treatment
group regarding rescue medication, pain disability index after 26
weeks, and quality of life subscales. For example, in the no
treatment group rescue medication was used on more days during
the weeks five to eight (8.2 [5.7;10.7] days) than in the verum
group (3.7 [1.2;6.3] days, P=0.001). However, results in the
verum and the placebo group for rescue medication and all other
secondary outcome parameters were not significantly different
(Table 3).
Of the 99 patients in both intervention groups, 71 patients
reported at least one adverse event (verum group n=37, placebo
group n=34). Reported adverse events included a hematoma at
the injection site (verum group n=8 (15.7%) vs. placebo group
n=5 (10.4%), P=0.546), common cold (9 (17.6%) vs. 5 (10.4%),
P=0.379) and pain (17 (33.3%) vs. 17 (35.4%), P=0.814). We did
not observe any significant or relevant differences between both
groups.
Verum n=50 No treatment n=49 Placebo n=43
Verum
vs no
treatment
Verum vs
placebo
mean 95%CI mean 95%CI mean 95%CI P value P value
26 weeks 80.8 71.7 ; 89.9 80.7 71.2 ; 90.1 71.6 61.4 ; 81.7 0.982 0.182
Mental health
8 weeks 64.9 60.7 ; 69.1 70.9 66.7 ; 75.2 68.2 63.7 ; 72.8 0.047 0.283
26 weeks 70.2 65.8 ; 74.6 70.1 65.6 ; 74.6 67.9 63.0 ; 72.8 0.970 0.487
1data were adjusted using a linear mixed model with a random-effects parameter for study site, and the respective baseline value as fixed covariate.
#lower values are better, *higher values are better.
doi:10.1371/journal.pone.0026166.t003
Table 3. Cont.
Table 4. Sensitivity and additional analyses of the visual analogue scale (VAS), unadjusted data, per-protocol analysis, analysis with
imputation of missing values and models with additional covariates.
Verum No treatment Placebo
Verum vs no
treatment
Verum vs
placebo
mean
VAS CI mean VAS CI mean VAS CI P value P value
Unadjusted analysis
8 weeks (97.5% CI) 36.6 27.8;45.4 52.6 46.2;59.1 43.4 33.3;53.4 0.001 0.244
26 weeks (95% CI) 37.5 29.7;45.4 46.1 39.2;53.1 38.5 30.7;46.3 0.104 0.858
Per-protocol analysis
8 weeks (97.5% CI) 41.5 29.6;53.3 52.9 41.8;64.1 37.8 25.9;49.8 0.035 0.518
26 weeks (95% CI) 38.5 27.2;49.7 45.2 34.3;56.0 36.5 25.3;47.7 0.232 0.732
Imputation of missing values VAS at 8
weeks (97.5% CI)
Maximum likelihood method* 37.2 27.7;46.8 52.7 43.3;62.1; 42.3 32.1;52.4 0.002 0.329
Worst case method
# 38.4 30.1;46.7 51.0 42.7;59.3 37.8 29.2;46.4 0.016 0.921
Primary model with other additional
covariates VAS at 8 weeks (97.5% CI)
Gender 37.1 25.2;48.9 53.0 41.8;64.2 41.8 30.1;53.6 0.002 0.367
Expectation of the therapy with the
verum (patient)
33.5 21.0;45.9 48.7 35.9;61.5 38.2 25.5;50.9 0.002 0.360
Expectation of the therapy with the
verum (physician)
36.9 24.9;49.0 52.8 41.2;64.5 41.8 29.9;53.7 0.002 0.346
*regression analysis including the baseline VAS, age and gender.
#missing values in the verum group were imputed by the worst possible value (100) while missing values in the placebo and no treatment groups were imputedb yt h e
best possible value (0).
doi:10.1371/journal.pone.0026166.t004
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were asked to guess what treatment intervention had been
administered to each patient (Table 5). Treatment with Disci/
Rhus toxicodendron. compositum could not be identified more
often than expected by chance. The allocation of each guess did
not differ significantly between the treatment groups (physicians
P=0.292, patients P=0.255).
Neither treatment expectation of the patients nor the physicians
had a significant influence on the patients’ outcome.
Discussion
In our study, we found that the homeopathic preparation Disci/
Rhus toxicodendron compositum was not superior to placebo.
Compared to no treatment the injection treatment resulted in
significant and clinically relevant short-term chronic back pain
relief and reduction of rescue medication. In addition, it was safe.
The main strengths of this trial are the double-blind randomized
placebo controlled design with a multicenter approach, the
inclusion of a no treatment group, the relatively large sample size
for a trial on CAM, and the good compliance and follow-up rates.
Concealed treatment allocation and sustained blinding in the
treatment groups could be ensured for both doctors and patients.
Patients were recruited and treated at very different study sites
with different clinical settings such as university outpatient clinics,
primary care practices, and orthopedic practices to ensure better
external validity of the results. With the three armed design we
were able to evaluate the impact of the whole intervention (verum
group vs. no treatment group) as well as the specific effect of the
drug alone (verum group vs. placebo group).
The primary outcome measure (VAS) is a validated and
sensitive tool which is widely used to measure pain. The VAS was
measured after eight weeks and displays the effect of the
intervention at the end of a treatment phase. In addition we
evaluated long term effects after 26 weeks. We included a number
of secondary outcome measures such as medication intake, back
function and quality of life. Those together with the sensitivity and
per protocol analyses help to confirm the results.
The placebo control we used was an isotonic saline solution
which could not be distinguished from the verum. Like in the
verum group, at every treatment session the isotonic solution was
injected subcutaneously into the lower back. One may argue that
physiological effects caused by the insertion of the needle and the
injection of a solution cannot be ruled out. For example, according
to acupuncture research those effects could have been mediated by
diffuse noxious inhibitory control [21,22]. Thus, the injections
themselves, even without an active ingredient, can affect pain
perception. Consequently, according to Kaptchuk the placebo
control we used can be described as very powerful [23]. A recent
study on acupuncture shows that pricking the skin without
penetration can reduce pain in low back pain patients [24]. Our
study had the power to detect a clinically relevant difference on
VAS between the verum and no treatment (according Ostelo [25]
around 15 mm). However, between the verum and the placebo
group no significant difference was shown on the VAS which
might only be statistically significant in a much larger sample.
Another limitation of this trial might be the therapy duration
that we chose. We evaluated the effect of 12 therapy sessions
within eight weeks. This duration of the therapy might be too short
to cause substantial effects in patients with long term chronic low
back pain of 15 years. Moreover, today a multimodal approach for
patients with chronic low back pain without injection therapy is
recommended [2,3,4].
As this was the first prospective study on Disci/Rhus
toxicodendron compositum in patients with chronic low back
pain we lack the possibility to compare our results with results
from other studies. The effectiveness of injection therapy in
treating low back pain independent of the injected solution was
shown by a study with 110 patients who received either glucose-
lignocaine or saline injections [26]. And according to a Cochrane
review on injection therapy for subacute and chronic low back
pain there is no strong evidence for or against the use of any type
of injection therapy [13]. Another Cochrane review, on acupunc-
ture and dry-needling for low back pain, concludes that
acupuncture and dry-needling may be useful adjuncts to other
therapies for chronic low-back pain [27]. A systematic review [28]
from 2008 indicates that the injection of sterile water can be used
as a treatment option for low back pain during labor. Sterile water
seems to be more effective than isotonic solutions [29] which might
be explained by an osmotic irritation as well as mechanical
stimulation in the injection area because of the increased local
pressure in the tissue, a kind of sensory stimulation [28]. Local
anti-nociceptive effects mediated by adenosine A1 receptors as
recently shown for acupuncture by Goldman et al. in Nature
Neuroscience are also possible [30]. This suggests that injections
can have strong specific effects. Moreover, local subcutaneous
injections of safe substances such as water and saline solution
might have its role in the treatment of low back pain and further
research would be helpful. We conclude that no superiority of
Disci/Rhus toxicodendron compositum over placebo injections
could be shown for patients with chronic low back pain. However,
injection therapy was safe and a short term reduction of pain and
rescue medication was achieved by subcutaneous injections of
both verum and placebo when compared to no treatment. The
Table 5. Guesses of group allocation as a surrogate for blinding.
Group assignment P value*
Physicians’ guesses Verum Placebo
Verum 28 (59.6%) 20 (47.6%) 0.292
Placebo 19 (40.4%) 22 (52.4%)
Patients’ guesses Verum Placebo P value*
Verum 14 (28.0%) 9 (20.9%) 0.255
Placebo 20 (40.0%) 13 (30.2%)
‘‘I don’t know’’ 16 (32.0%) 21 (48.8%)
*Chi-square test.
doi:10.1371/journal.pone.0026166.t005
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water and saline solution for low back pain management should be
further investigated.
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